Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE-Reference-Cited by-同舟云学术

Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE

Published:2020-11-25 Issue:1 Volume:38 Page:772-781
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Li Zhan-Guo,Hu Jian-Kang,Li Xiang-Pei,Yang Yue,Li Xing-Fu,Xu Jian-Hua,Zhang Xiao,Xu Jian,Bao Chun-De,He Dong-Yi,Li Zhi-Jun,Wang Guo-Chun,Zuo Xiao-Xia,Liu Yi,Xiao Zheng-Yu,Chen Jin-Wei,Xin Xia-Fei,Li Jing-Yang,Jiang Lin-Di,Liu Meng-Ru,Ji Fei,Li Chen-Ge

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-020-01572-y.pdf

Reference16 articles.

1. Gerhold K, Richter A, Schneider M, et al. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology (Oxford). 2015;54:1858–66.

2. Guo Q, Wang Y, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.

3. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.